Islam M Miligy

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/106887/publications.pdf

Version: 2024-02-01

41	953	393982	476904
papers	citations	19 h-index	29 g-index

43	43	43	1484
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours. Breast Cancer Research, 2018, 20, 21.	2.2	85
2	Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ. Histopathology, 2017, 71, 258-268.	1.6	58
3	Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival. Breast Cancer Research and Treatment, 2020, 182, 267-282.	1.1	58
4	Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast. Modern Pathology, 2018, 31, 1226-1236.	2.9	56
5	Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer. Breast Cancer Research and Treatment, 2019, 174, 387-399.	1.1	53
6	Diagnostic concordance and discordance in digital pathology: a systematic review and meta-analysis. Journal of Clinical Pathology, 2021, 74, 448-455.	1.0	48
7	Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer. Modern Pathology, 2021, 34, 1271-1281.	2.9	43
8	A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk. Breast Cancer Research, 2019, 21, 83.	2.2	39
9	Prolyl-4-hydroxylase Î± subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS). British Journal of Cancer, 2018, 119, 1518-1526.	2.9	32
10	Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ. Journal of Clinical Pathology, 2020, 73, 76-82.	1.0	31
11	Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 493-502.	1.4	30
12	The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution. British Journal of Cancer, 2019, 120, 1075-1082.	2.9	27
13	Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention. Cancer Research, 2018, 78, 6818-6827.	0.4	26
14	The prognostic significance of immune microenvironment in breast ductal carcinoma in situ. British Journal of Cancer, 2020, 122, 1496-1506.	2.9	26
15	Invasion in breast lesions: the role of the epithelialâ€“stroma barrier. Histopathology, 2018, 72, 1075-1083.	1.6	25
16	Current trials to reduce surgical intervention in ductal carcinoma in situ of the breast: Critical review. Breast, 2017, 35, 151-156.	0.9	24
17	Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ. Modern Pathology, 2018, 31, 1807-1815.	2.9	23
18	Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ. Modern Pathology, 2019, 32, 1460-1472.	2.9	23

#	Article	IF	Citations
19	PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers. Cancer Letters, 2020, 469, 124-133.	3.2	22
20	Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer. Breast Cancer Research and Treatment, 2020, 181, 541-551.	1.1	22
21	Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma. Journal of Pathology, 2019, 248, 326-338.	2.1	21
22	Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ. Modern Pathology, 2019, 32, 639-649.	2.9	19
23	The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma. Npj Breast Cancer, 2020, 6, 9.	2.3	19
24	The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer. Breast Cancer Research and Treatment, 2020, 179, 79-90.	1.1	18
25	The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma inÂsitu. Histopathology, 2019, 74, 1025-1035.	1.6	16
26	Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer. Breast Cancer Research and Treatment, 2020, 179, 557-564.	1.1	13
27	ATM Regulated PTEN Degradation Is XIAP E3 Ubiquitin Ligase Mediated in p85Î± Deficient Cancer Cells and Influence Platinum Sensitivity. Cells, 2019, 8, 1271.	1.8	12
28	Molecular disruption of DNA polymerase Î² for platinum sensitisation and synthetic lethality in epithelial ovarian cancers. Oncogene, 2021, 40, 2496-2508.	2.6	12
29	FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers. Cancers, 2021, 13, 1866.	1.7	12
30	Geometric characteristics of collagen have independent prognostic significance in breast ductal carcinoma in situ: an image analysis study. Modern Pathology, 2019, 32, 1473-1485.	2.9	11
31	Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patientsÂundergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio â‰¥2.0, HER2) Tj ETQq1 1 0.784314 rgBT	2.1	11
32	Ligase 1 is a predictor of platinum resistance and its blockade is synthetically lethal in XRCC1 deficient epithelial ovarian cancers. Theranostics, 2021, 11, 8350-8361.	4.6	10
33	Surgical management of ductal carcinoma in situ of the breast: A large retrospective study from a single institution. Breast Journal, 2019, 25, 1143-1153.	0.4	7
34	ecancermedicalscience. Ecancermedicalscience, 2014, 8, 404.	0.6	5
35	The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ. British Journal of Cancer, 2020, 123, 1513-1520.	2.9	4
36	A Quantitative Centrosomal Amplification Score Predicts Local Recurrence of Ductal Carcinoma In Situ. Clinical Cancer Research, 2020, 26, 2898-2907.	3.2	4

#	Article	IF	Citations
37	The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ. Breast Cancer Research and Treatment, 2021, 188, 53-63.	1.1	4
38	The frequency and clinical significance of DNA polymerase beta (POLÎ²) expression in breast ductal carcinoma in situ (DCIS). Breast Cancer Research and Treatment, 2021, 190, 39-51.	1.1	1
39	Lessons from a breast cell annotation competition series for school pupils. Scientific Reports, 2022, 12, 7792.	1.6	1
40	Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ. Pathobiology, 2022, 89, 382-392.	1.9	1
41	Abstract P6-10-21: Evaluation of genomic changes in ductal carcinomain situas potential biomarkers of recurrence risk. , 2020, , .		0